Europeiska unionen - svenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostatiska neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - bröst-neoplasmer - antineoplastiska medel - talzenna är indicerat som monoterapi för behandling av vuxna patienter med könsceller brca1/2 mutation, som har her2-negativa lokalt avancerad eller metastaserande bröstcancer. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patienter med hormon receptor (hr)-positiv bröstcancer bör ha behandlats med en före endokrina-baserad terapi, eller anses vara olämpliga för endokrina-baserad terapi.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemiska preparat - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatit, atopisk - andra dermatologiska preparat - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiska medel - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Europeiska unionen - svenska - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ögonsjukdomar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamindimesilat - kapsel, hård - 60 mg - propylenglykol hjälpämne; lisdexamfetamindimesilat 60 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamindimesilat - kapsel, hård - 20 mg - propylenglykol hjälpämne; lisdexamfetamindimesilat 20 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamindimesilat - kapsel, hård - 40 mg - lisdexamfetamindimesilat 40 mg aktiv substans; propylenglykol hjälpämne